Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Diagn Microbiol Infect Dis ; 103(3): 115715, 2022 Jul.
Article in English | MEDLINE | ID: mdl-35598409

ABSTRACT

Chlamydia (C.) abortus is an emerging zoonotic pathogen. Since data on its antimicrobial susceptibility are lacking, we aimed to determine minimal inhibitory (MIC) and minimal bactericidal concentrations (MBC) for azithromycin and doxycycline in HeLa-cells and primary human macrophages (M1). We also examined the MDM2-p53-inhibitor nutlin-3, an anti-infective imidazoline analog. Azithromycin and doxycycline demonstrated MICs and MBCs equal or below their peak serum concentrations (PSC) after standard dosing in both cell types. While doxycycline exhibited an MIC 64-fold and an MBC 4-fold below its PSC in HeLa-cells, the MIC of azithromycin was 4-fold below, the MBC equal to the PSC. However, azithromycin revealed lower MBCs in M1. The pharmacological advantage of azithromycin accumulation in phagocytes and their role as chlamydial reservoirs remain uncertain. However, our data suggest possible therapeutic advantages of doxycycline in epithelial cells and we provide first evidence for an anti-C. abortus effect of nutlin-3 in M1.


Subject(s)
Anti-Bacterial Agents , Chlamydia Infections , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/therapeutic use , Azithromycin/pharmacology , Chlamydia , Chlamydia trachomatis , Doxycycline/pharmacology , Doxycycline/therapeutic use , Epithelial Cells , Humans , Imidazoles , Macrophages , Piperazines , Proto-Oncogene Proteins c-mdm2/pharmacology , Tumor Suppressor Protein p53/pharmacology , Tumor Suppressor Protein p53/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...